Not for direct or indirect publicationor distribution within or in the United States of America, Australia, Canada,or Japan, or any other jurisdiction where such publication or distributionwould be unlawful. Please note the important information at the end of thisannouncement.
‍

Another record quarter for Cantourage:EUR 27.9 million* in Q2 2025 – full-year revenue for 2024 already exceeded

- EUR 27.9 million* revenue in Q2 2025

- EUR 54.0 million* revenue year-to-datein 2025

-            Prevention of Philip Schetter assole member of the Management Board – Patrick Hoffmann appointed to theManagement Board

Cantourage Group SE (hereinafter"Cantourage"; ISIN: DE000A3DSV01, www.cantourage.com), Europe's leadingpublicly traded medical cannabis company, continued its impressive growthtrajectory in the second quarter of 2025, achieving the strongest quarter inthe company's history with revenue of EUR 27.9 million*. This brings revenue toEUR 54.0 million* at the mid-year point, exceeding the previous year's totalannual revenue (EUR 51.4 million*). Compared to the same period last year, thisrepresents revenue growth of over 130 percent (Q2 2024: EUR 12.0 million*).

"In a highly competitive marketenvironment, we continue to see strong demand for Cantourage products – both inGermany and internationally," says Bernhard Retzer, Global Sales Directorat Cantourage. "With additional processing capacities in Europe, newsuppliers, and strong partnerships within the industry, we are ideallypositioned to continue operating successfully in the market in thefuture."

As communicated in the ad hocannouncement on July 9, 2025, Mr. Philip Schetter will not be performing hisduties as CEO of Cantourage Group SE until further notice. The company will notprovide any further details on the personal reasons for his absence. However,Mr. Schetter's full return to his duties is firmly planned. As Mr. Schetter hadpreviously served as the sole member of the Management Board of Cantourage, itwas necessary to fill the position immediately in order to ensure that thecompany remained capable of acting at all times. With Cantourage founderPatrick Hoffmann, who has shaped the company from the outset and hasaccompanied it as Deputy Chairman of the Supervisory Board since its IPO, theSupervisory Board was able to appoint at short notice a person who is veryfamiliar with the day-to-day operations of the company. Together with themanagement team of the subsidiaries, Mr. Hoffmann will ensure the smoothrunning of day-to-day operations and continue to drive forward the successful growthcourse of recent months until Mr. Schetter's full return.

Patrick Hoffmann comments: "Mr.Schetter has had a decisive and very successful influence on the development ofCantourage over the past four years. The Supervisory Board and the entire teamwould like to thank him for his extraordinary commitment. We are alreadylooking forward to his return to the company's management."

About Cantourage
‍Cantourage is a leading European company for the production anddistribution of medical cannabis. Cantourage enables growers worldwide to sellproducts in European medical markets. Founded in 2019, the company works withmore than 60 cannabis growers from 18 countries. Cantourage ensures the highestpharmaceutical quality standards along the value chain and offers products inall relevant market segments: dried flowers, extracts, dronabinol, andcannabidiol. The company has been listed on the Frankfurt Stock Exchange sinceNovember 11, 2022, and is traded under the ticker symbol "HIGH."

* All figures are preliminary,unaudited, and unconsolidated.

‍

Press contact at Cantourage:

Manuel Taverne| taverne@cantourage.com

‍

This announcement does not constitute a public offer or an advertisement fora public offer to sell securities, in particular within the meaning ofRegulation (EU) 2017/1129 (Prospectus Regulation).

‍